Omicron News and Research

RSS

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-specific cluster of differentiation 8 (CD8+) T cell responses.

12 Apr 2022

Comparing SARS-CoV-2 Delta and Omicron waves in Germany

In a recent study posted to the medRxiv* preprint server, researchers compared the outcomes and characteristics of hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients during the SARS-CoV-2 Delta and Omicron variants’ dominant periods in Germany.

12 Apr 2022

Antibody response following Omicron BA.2 infection is lower than BA.1

In a recent report posted to the medRxiv* preprint server, researchers determined immune responses generated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineage infections in prior virus-infected and naïve subjects.

12 Apr 2022

Severe COVID-19 extremely rare among children

A new Journal of Infection study describes the findings in children who contracted SARS-CoV-2 infection in England.

12 Apr 2022

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell immune responses in 93 percent of patients with B-cell deficiencies, including many patients with leukemia and lymphoma, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

12 Apr 2022

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

A clinical study from Spain recently confirmed laboratory experiments made by researchers of Goethe University Frankfurt and University of Kent who showed that the protease inhibitor aprotinin prevented cells to be infected by SARS-CoV2.

12 Apr 2022

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

They might look like cells and act like cells. But a new potential COVID-19 treatment is actually a cleverly disguised trickster, which attracts viruses and binds them, rendering them inactive.

12 Apr 2022

Study identifies risk factors for severe COVID-19 in hospitalized children in Canada

Researchers evaluated the risk factors for severe COVID-19 among hospitalized children in Canada.

12 Apr 2022

Early COVID-19 reinfections possible within 60 days of initial infection

Researchers reported that COVID-19 reinfections could occur within 60 days of the initial infection.

12 Apr 2022

Epidemiologic characteristics of SARS-CoV-2 Omicron and Delta variant infection cases in Cantabria, Spain

Researchers performed a comparative assessment of the key epidemiological characteristics such as secondary attack rates, transmission, serial interval, and incubation period of SARS-CoV-2 infections by the Omicron and Delta variants.

12 Apr 2022

Exploring vaccine effectiveness against SARS-CoV-2 Omicron and Delta variants in adolescents

A new study assessed the effectiveness of the BNT162b2 SARS-CoV-2 vaccine against Delta and Omicron variants in adolescents.

12 Apr 2022

Colorado moves toward statewide coverage of wastewater surveillance

On a Sunday morning in March 2020, right at the start of the pandemic, an article in Popular Mechanics caught engineer Pieter Van Ry's eye. It had a catchy title: "How Poop Offers Hints About the Spread of Coronavirus."

12 Apr 2022

Differences in symptoms and risk of hospitalization following infection with Omicron or Delta SARS-CoV-2 variants among vaccinated people

A recent study assessed the prevalence of SARS-CoV-2 symptoms and the risk of hospitalization in vaccinated individuals infected with SARS-CoV-2 Omicron and Delta variants.

12 Apr 2022

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

A recent study illustrated the enhanced distinct clustering of pseudotyped particles (PPs) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant.

12 Apr 2022

Inflammation weakens odor signals and may be responsible for COVID19 loss of smell

Anosmia, the loss of smell, is a frequent and often long-term symptom associated with COVID-19 that can severely burden a person's quality of life, making it extremely difficult to taste foods, detect airborne hazards in the environment and carry out other functions dependent on the sense.

11 Apr 2022

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Researchers used cryogenic electron microscopy (cryo-EM) to determine the structure of the spike (S) protein of BA.2 sub-variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and compared them with previously determined S structures of Omicron's BA.1 sub-variant.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Omicron News and Research

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

Comparing SARS-CoV-2 Delta and Omicron waves in Germany

Antibody response following Omicron BA.2 infection is lower than BA.1

Severe COVID-19 extremely rare among children

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

Study identifies risk factors for severe COVID-19 in hospitalized children in Canada

Early COVID-19 reinfections possible within 60 days of initial infection

Epidemiologic characteristics of SARS-CoV-2 Omicron and Delta variant infection cases in Cantabria, Spain

Exploring vaccine effectiveness against SARS-CoV-2 Omicron and Delta variants in adolescents

Colorado moves toward statewide coverage of wastewater surveillance

Differences in symptoms and risk of hospitalization following infection with Omicron or Delta SARS-CoV-2 variants among vaccinated people

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

Inflammation weakens odor signals and may be responsible for COVID19 loss of smell

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

SARS-CoV-2 Omicron BA.2 sublineage outbreak aggravated by low population immunity in Hong Kong

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News